WO2006106529A1 - A co-spray dried composition of cefepime with base and process for preparation thereof - Google Patents
A co-spray dried composition of cefepime with base and process for preparation thereof Download PDFInfo
- Publication number
- WO2006106529A1 WO2006106529A1 PCT/IN2006/000114 IN2006000114W WO2006106529A1 WO 2006106529 A1 WO2006106529 A1 WO 2006106529A1 IN 2006000114 W IN2006000114 W IN 2006000114W WO 2006106529 A1 WO2006106529 A1 WO 2006106529A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cefepime
- acid addition
- solution
- aqueous solution
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Definitions
- the present invention provides sterile composition of a cefepime with a pharmaceutically acceptable non-toxic organic and inorganic base obtained by co spray drying of aqueous solution of composition that contains non-sterile cefepime and non-sterile pharmaceutically acceptable non-toxic organic and inorganic bases.
- the present invention further relates to provide a process for preparation of the stable composition of cefepime and pharmaceutically acceptable base obtained by co spray drying.
- the stable composition of cefepime and pharmaceutically acceptable base obtained by co spray drying exist in an amorphous form.
- cefepime either because of its poor solubility in water or its inherent instability in zwitterionic form, is administrated in the form of acid addition salts.
- the marketed MAXIPIME ® formulation of cefepime contains cefepime dihydrochloride, monohydrate salt of formula Il as the active ingredient.
- US '301 patent discloses selective process for preparation of the crystalline acid addition salts which comprises of dissolving the zwitterion in a mineral acid and causing crystallization by addition of a solvent such as acetone or isopropanol, followed by filtration, washing and drying to obtain the acid addition salt.
- This process is usually conducted in sterile conditions and in an aqueous medium resulting in an acidic solution thereby leading to extensive corrosion of the reactor vessel, which calls for the use of special corrosion- resistant reactors.
- the abovementioned acid addition salts of cefepime cannot be administered directly after reconstitution with sterile water as they provide acidic solutions which provoke unacceptable irritation on intravenous administration and unacceptably painful sensation on intramuscular administration. Also some of the acid addition salts have reduced solubility's which are insufficient for typical injectable compositions. To overcome these limitations, the acid addition salt compositions are mixed with buffering agents during reconstitution to provide a pH of about 3.5 to about 7.
- the admixtures mentioned hereinabove require the use of sterile raw materials and totally aseptic and dry conditions, thus rendering the process expensive.
- the physical admixtures of the crystalline, stable cefepime acid addition salts and L(+) arginine are known to exhibit poor solid state stability at elevated temperatures.
- anhydrous L(+) arginine is extremely hygroscopic and it can accept two moles of water of crystallization.
- the physical admixtures need to be vacuum-dried under a variety of conditions, preferably, using the lyophilization technique, to remove free extraneous water.
- U.S. Pat. No. 4,808,617 claims a stable antibiotic composition consisting of amorphous cefepime zwitterion formed by lyophilization or co solvent precipitation of an aqueous solution of cefepime zwitterion and a salt or mixture of salts.
- Solvent such as acetone or isopropanol is used to precipitate the zwitterion-salt complex.
- the salt is one wherein the cation is selected from the group consisting of sodium, lithium, calcium and magnesium and the anion is selected from chloride, bromide and iodide.
- U.S. Pat. No. 5,095,011 claims a stable, amorphous, lyophilized dihydrochloride salt of cefepime and a reconstituted, injectable composition which comprises an effective amount of the amorphous salt in an aqueous solution having a suitable organic or inorganic base wherein the pH of the resulting solution is between 3.0- 7.0.
- the US patent No. 3,984,403 discloses a method to provide composition comprising certain acid cephalosporins and bases such as l-arginine and l-lysine and to provide the process for their preparation.
- the process involves treatment of acid cephalosporin part (in the form of zwitterion or sodium salt) with base part (I- lysine or l-arginine) in approximately equivalent proportion in water, at or below room temperature to provide the reaction product in water followed by its isolation.
- the isolation method involves co-precipitation of mixture comprising cephalosporin acid and l-arginine by addition of ethanol, followed by filtration of solid and re dissolving the isolated solid in water and finally lyophilization of the aqueous solution to obtain amorphous composition
- the other isolation method involves initial lyophilization of reaction mixture comprising cephalosporin acid and a l-arginine to get solid followed by dissolving the isolated solid in water, co- precipitation of composition by addition of ethanol and isolation of solid by filtration.
- Use of lyophilization method renders the process costlier and the multi- step work up makes it laborious.
- a stable composition cefepime and a pharmaceutically acceptable non-toxic organic or inorganic base can be obtained by spray drying the solution containing mixture of non-sterile of cefepime salt or solvates thereof and non-sterile non-toxic base.
- the spray " drying method does not have stringent requirements as that of prior art processes as described above. More over, the composition obtained by spray drying can be administered as an injectable directly after reconstitution with water.
- the present invention relates to sterile composition of a cefepime with a pharmaceutically acceptable non-toxic organic and inorganic base obtained by simple and cost effective method such as co spray drying of solution composition that contains non sterile cefepime and non sterile pharmaceutically acceptable non-toxic organic and inorganic bases.
- the sterile composition obtained by the present invention has high purity, good thermal stability and obtained in amorphous or substantially amorphous form.
- co spray drying utilised herein to mean spray drying of aqueous solution of composition containing cefepime and non-toxic base to give sterile mixture of both cefepime as well as non toxic base.
- the sterile composition thus obtained is termed as "co spray dried composition"
- the process does not require separate facilities for the preparation of sterile acid addition salt of cefepime and of sterile pharmaceutically acceptable base, and a sterile blender to prepare their admixture.
- the present invention provides a simple, cost-effective method for preparation of cefepime dihydrochloride-L (+) arginine mixture useful in the pharmaceutical composition.
- the present invention provides a stable, composition of Cefepime with a pharmaceutically acceptable organic or inorganic base, which can be administered directly after reconstitution with sterile water without further pH adjustment.
- the experimental conditions are simple and applicable to large-scale production.
- the present invention provides a sterile and stable composition of cefepime acid addition salt with a pharmaceutically acceptable non-toxic organic or inorganic base that is obtained by spray drying.
- a process for manufacture of injectable cefepime composition by a spray drying which is comprising of, (i) dissolving a composition containing mixture of cefepime acid addition salt and a pharmaceutically acceptable non-toxic organic or inorganic base in water at 0-30 0 C, preferably at 0-1O 0 C to obtain a clear aqueous solution having a pH in the range of 3.0-7.0,
- the sterile dry powder can be filled into a vial or other container.
- cefepime acid addition salt and a pharmaceutically acceptable non-toxic organic or inorganic base employed in the process can be sterile or non-sterile.
- Suitable acid addition salts of cefepime include H 2 SO 4 , di-HNO 3 , HCI, di-HCI, and sesqui- H 3 PO 4 salts and their solvates.
- Suitable non-toxic organic or inorganic bases which may be used in the composition according to the invention include, for example, sodium citrate, potassium citrate, N-methylglucosamine, N-methylglucamine, L (+) lysine, L (+) arginine tris(hydroxymethyl) aminomethane, NaHCO 3 , Na 2 CO 3 , NaH 2 PO 4 , Na 2 HPO 4 , Na 3 PO 4 , KHCO 3 , K 2 CO 3 , KH 2 PO 4 , K 2 HPO 4 and K 3 PO 4 .
- Most preferred bases in the composition are L (+) lysine and L (+) arginine.
- the molar ratio of cefepime acid addition salt to the pharmaceutically acceptable base in the composition can be in the range of 1 :1 to 1:5, preferably in the range of 1: 2 to 1:3.
- composition containing mixture of non-sterile cefepime and a non-sterile pharmaceutically acceptable non-toxic organic or inorganic base was dissolved in water at 0-4O 0 C, preferably at 0-1O 0 C, most preferably at 0-5 Or O".
- composition containing non-sterile cefepime and non-sterile base can also perform the invention.
- a non-sterile composition containing various crystalline acid additions salts of cefepime such as sulfuric, di-nitric, monohydrochloric, dihydrochloric, and di- and sesquiorthophosphoric acid addition salts or solvates thereof can be used for the process of present invention.
- composition of cefepime and L (+) arginine obtained by co spray drying was amorphous as per powder XRD pattern shown in figure 1.
- the sterile composition obtained by spray drying method on reconstitution with sterile water gives an injectable solution having pH in the range of 3.0-7.0, preferably in the pH range 4- 4.5, which is amenable for I. M. or I.V. administration directly without further pH adjustment.
- Such a sterile composition was found to be stable.
- the thermal stability data of amorphous composition containing cefepime and L (+) argnine in injection water is shown in Table 1.
- Amorphous composition of cefepime hydrochloride and L- (+) arginine (gm) was dissolved in injection water and analyzed as per USP method.
- the starting material i.e. composition containing admixture of crystalline cefepime dihydrochloride monohydrate and L (+) arginine available from the market was used.
- the spray drying was carried out by using Buchi mini spray dryer B-191.
- composition containing cefepime dihydrochloride monohydrate and L-arginine (50 gm) was dissolved in demineralized water (50 ml) at 25-30 0 C.
- the clear solution was filtered through 0.2 micron membrane filter. Filter was washed with water (10 ml). Combined filtrate was subjected for spray drying in the following setting of spray dryer.
Abstract
Stable and sterile composition of cefepime and a process for preparing the same. Amorphous composition containing cefepime acid addition salt or solvates thereof and organic or inorganic base obtained by spray drying of their aqueous solution. The process comprises dissolving a composition containing mixture of cefepime acid addition salt and a pharmaceutically acceptable non-toxic organic or inorganic base in water to obtain aqueous solution, filtration of aqueous solution through 0.2 micron membrane filter and subjecting the clear aqueous solution to spray drying, or dissolving a cefepime acid addition salt in water, dissolving a pharmaceutically acceptable non-toxic organic or inorganic base in water, addition of solution from operation (v) to solution from operation (iv) at 0-30°C, preferably at 0-10°C to obtain a solution having a pH in the range of 3.0-7.0, filtration of aqueous solution through 0.2 micron membrane filter, and subjecting the clear aqueous solution to spray drying.
Description
A CO SPRAY DRIED COMPOSITION OF CEFEPIME WITH BASE AND PROCESS FOR PREPARATION THEREOF
FIELD OF THE INVENTION
The present invention provides sterile composition of a cefepime with a pharmaceutically acceptable non-toxic organic and inorganic base obtained by co spray drying of aqueous solution of composition that contains non-sterile cefepime and non-sterile pharmaceutically acceptable non-toxic organic and inorganic bases. The present invention further relates to provide a process for preparation of the stable composition of cefepime and pharmaceutically acceptable base obtained by co spray drying. The stable composition of cefepime and pharmaceutically acceptable base obtained by co spray drying exist in an amorphous form.
BACKGROUND OF THE INVENTION The chemical entity, 7-[α- (2-aminothiazol-4-yl)-α-(Z)-methoxyiminoacetamido]-3- [(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate, generically known as cefepime, is a semi synthetic, fourth generation injectable cephalosporin antibiotic effective against infections caused by both Gram-positive and Gram-negative organisms. The compound, which exists in the zwitterion form, is represented by formula (I).
cefepime, either because of its poor solubility in water or its inherent instability in zwitterionic form, is administrated in the form of acid addition salts. The marketed
MAXIPIME® formulation of cefepime contains cefepime dihydrochloride, monohydrate salt of formula Il as the active ingredient.
U.S. Pat. No. 4,406,899 discloses cefepime in the zwitterion form and the corresponding acid addition salts. However, there is neither any enabling disclosure for preparation of the acid addition salts nor any mention of the solid- state nature of the product in the specification.
Crystalline acid addition salts of cefepime such as the H2SO4, di-HNO3, HCI, di- HCI, and sesqui-H3Pθ4 salts and their solvates are disclosed in U.S. Pat. No. 4,910,301. The patent mentions that the zwitterion form disclosed in US '899 is unstable both as a dry powder and as an injectable composition and requires special packaging and storage conditions. In contrast, US '301 patent claims that the crystalline material obtained therein exhibits excellent thermal stability and is hence more suited for formulation into an injectable dosage form. This implies that the zwitterion form of US '899 is probably an amorphous like crystalline material which exhibits very poor stability on storage.
Further, US '301 patent discloses selective process for preparation of the crystalline acid addition salts which comprises of dissolving the zwitterion in a mineral acid and causing crystallization by addition of a solvent such as acetone or isopropanol, followed by filtration, washing and drying to obtain the acid addition salt. This process is usually conducted in sterile conditions and in an
aqueous medium resulting in an acidic solution thereby leading to extensive corrosion of the reactor vessel, which calls for the use of special corrosion- resistant reactors.
However, the abovementioned acid addition salts of cefepime cannot be administered directly after reconstitution with sterile water as they provide acidic solutions which provoke unacceptable irritation on intravenous administration and unacceptably painful sensation on intramuscular administration. Also some of the acid addition salts have reduced solubility's which are insufficient for typical injectable compositions. To overcome these limitations, the acid addition salt compositions are mixed with buffering agents during reconstitution to provide a pH of about 3.5 to about 7.
Another alternative to overcome the limitations associated with acidic solutions is utilizing the acid addition salts in physical admixture with a pharmaceutically acceptable base. Such a composition is disclosed in U.S. Pat. No. 4,994,451 and U.S. Pat. No. 5,244,891, wherein, injectable compositions of temperature stable acid addition salts of cefepime in physical admixture with a pharmaceutically acceptable non-toxic organic or inorganic base, specifically, arginine in proportions to provide a pH of about 3.5 to about 7 on dilution with water to injectable concentration, are described. The physical admixture is prepared by blending the sterile salt and the base into a uniform blend, e.g. utilizing a standard blender in a dry atmosphere, and is then preferably filled into a vial or other container, all under aseptic conditions.
The admixtures mentioned hereinabove require the use of sterile raw materials and totally aseptic and dry conditions, thus rendering the process expensive. Moreover, the physical admixtures of the crystalline, stable cefepime acid addition salts and L(+) arginine are known to exhibit poor solid state stability at elevated temperatures. Also, anhydrous L(+) arginine is extremely hygroscopic and it can accept two moles of water of crystallization. The physical admixtures need to be
vacuum-dried under a variety of conditions, preferably, using the lyophilization technique, to remove free extraneous water.
U.S. Pat. No. 4,808,617 claims a stable antibiotic composition consisting of amorphous cefepime zwitterion formed by lyophilization or co solvent precipitation of an aqueous solution of cefepime zwitterion and a salt or mixture of salts.
Solvent such as acetone or isopropanol is used to precipitate the zwitterion-salt complex. The salt is one wherein the cation is selected from the group consisting of sodium, lithium, calcium and magnesium and the anion is selected from chloride, bromide and iodide. This patent further claims a stable solvates of antibiotic composition as mentioned above.
U.S. Pat. No. 5,095,011 claims a stable, amorphous, lyophilized dihydrochloride salt of cefepime and a reconstituted, injectable composition which comprises an effective amount of the amorphous salt in an aqueous solution having a suitable organic or inorganic base wherein the pH of the resulting solution is between 3.0- 7.0. Although the patent claims that the amorphous form of cefepime is stable, it requires lyophilization or freeze-drying. Lyophilization is not cost-effective and universal since it involves the utilization of an expensive lyophilizer and moreover, the method is exclusive to only those manufacturers who have such a facility. Also the composition requires external addition of suitable base during reconstitution.
The US patent No. 3,984,403 discloses a method to provide composition comprising certain acid cephalosporins and bases such as l-arginine and l-lysine and to provide the process for their preparation. The process involves treatment of acid cephalosporin part (in the form of zwitterion or sodium salt) with base part (I- lysine or l-arginine) in approximately equivalent proportion in water, at or below room temperature to provide the reaction product in water followed by its isolation. The isolation method involves co-precipitation of mixture comprising cephalosporin acid and l-arginine by addition of ethanol, followed by filtration of solid and re dissolving the isolated solid in water and finally lyophilization of the aqueous solution to obtain amorphous composition The other isolation method
involves initial lyophilization of reaction mixture comprising cephalosporin acid and a l-arginine to get solid followed by dissolving the isolated solid in water, co- precipitation of composition by addition of ethanol and isolation of solid by filtration. Use of lyophilization method renders the process costlier and the multi- step work up makes it laborious.
From the foregoing, it would be apparent that the prior art methods for manufacture of a sterile powder composition of injectable cefepime suffer from the following limitations, viz. i) use of mineral acid under aqueous conditions which results in extensive corrosion of the reactor vessel by the acidic solution and calls for the use of special corrosion-resistant reactors, ii) requires dry, sterile conditions for blending, thus adding to the cost of the process. iii) requires sterile raw materials which render the method expensive. iv) not cost-effective since such methods involve lyophilization, requiring capital expenditure for installation of a lyophilizer. v) the methods do not have universal applicability since they are exclusive only to those manufacturers who have an in-house lyophilizer.
We have found that a stable composition cefepime and a pharmaceutically acceptable non-toxic organic or inorganic base can be obtained by spray drying the solution containing mixture of non-sterile of cefepime salt or solvates thereof and non-sterile non-toxic base. The spray "drying method does not have stringent requirements as that of prior art processes as described above. More over, the composition obtained by spray drying can be administered as an injectable directly after reconstitution with water.
SUMMARY OF THE INVENTION The present invention relates to sterile composition of a cefepime with a pharmaceutically acceptable non-toxic organic and inorganic base obtained by simple and cost effective method such as co spray drying of solution composition
that contains non sterile cefepime and non sterile pharmaceutically acceptable non-toxic organic and inorganic bases. The sterile composition obtained by the present invention has high purity, good thermal stability and obtained in amorphous or substantially amorphous form.
The term "co spray drying" utilised herein to mean spray drying of aqueous solution of composition containing cefepime and non-toxic base to give sterile mixture of both cefepime as well as non toxic base. The sterile composition thus obtained is termed as "co spray dried composition"
The process does not require separate facilities for the preparation of sterile acid addition salt of cefepime and of sterile pharmaceutically acceptable base, and a sterile blender to prepare their admixture.
Thus, in one aspect of the present invention, there is provided a co-precipitated injectable cefepime composition, which exhibits good stability.
In another aspect, the present invention provides a simple, cost-effective method for preparation of cefepime dihydrochloride-L (+) arginine mixture useful in the pharmaceutical composition.
In yet another aspect, the present invention provides a stable, composition of Cefepime with a pharmaceutically acceptable organic or inorganic base, which can be administered directly after reconstitution with sterile water without further pH adjustment.
The experimental conditions are simple and applicable to large-scale production.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides a sterile and stable composition of cefepime acid addition salt with a pharmaceutically acceptable non-toxic organic or inorganic base that is obtained by spray drying.
In another aspect of the present invention, there is provided a process for manufacture of injectable cefepime composition by a spray drying which is comprising of, (i) dissolving a composition containing mixture of cefepime acid addition salt and a pharmaceutically acceptable non-toxic organic or inorganic base in water at 0-300C, preferably at 0-1O0C to obtain a clear aqueous solution having a pH in the range of 3.0-7.0,
(ii) filtration of aqueous solution through 0.2 micron membrane filter and (iii) subjecting the clear aqueous solution to spray drying, or
(i) dissolving a cefepime acid addition salt in water, (ii) dissolving a pharmaceutically acceptable non-toxic organic or inorganic base in water, (iii) addition of solution from operation (v) to solution from operation (iv) at 0-
3O0C, preferably at 0-100C to obtain a solution having a pH in the range of
3.0-7.0,
(iv) filtration of aqueous solution through 0.2 micron membrane filter and (v) subjecting the clear aqueous solution to spray drying.
The sterile dry powder can be filled into a vial or other container.
The cefepime acid addition salt and a pharmaceutically acceptable non-toxic organic or inorganic base employed in the process can be sterile or non-sterile.
Suitable acid addition salts of cefepime, which may be used in the composition according to the invention, include H2SO4, di-HNO3, HCI, di-HCI, and sesqui- H3PO4 salts and their solvates.
Suitable non-toxic organic or inorganic bases which may be used in the composition according to the invention include, for example, sodium citrate, potassium citrate, N-methylglucosamine, N-methylglucamine, L (+) lysine, L (+)
arginine tris(hydroxymethyl) aminomethane, NaHCO3, Na2CO3, NaH2PO4, Na2HPO4, Na3PO4, KHCO3, K2CO3, KH2PO4, K2HPO4 and K3PO4. Most preferred bases in the composition are L (+) lysine and L (+) arginine.
The molar ratio of cefepime acid addition salt to the pharmaceutically acceptable base in the composition can be in the range of 1 :1 to 1:5, preferably in the range of 1: 2 to 1:3.
The composition containing mixture of non-sterile cefepime and a non-sterile pharmaceutically acceptable non-toxic organic or inorganic base was dissolved in water at 0-4O0C, preferably at 0-1O0C, most preferably at 0-5Or O".
Using composition containing non-sterile cefepime and non-sterile base can also perform the invention. A non-sterile composition containing various crystalline acid additions salts of cefepime such as sulfuric, di-nitric, monohydrochloric, dihydrochloric, and di- and sesquiorthophosphoric acid addition salts or solvates thereof can be used for the process of present invention.
The composition of cefepime and L (+) arginine obtained by co spray drying was amorphous as per powder XRD pattern shown in figure 1.
The sterile composition obtained by spray drying method on reconstitution with sterile water, gives an injectable solution having pH in the range of 3.0-7.0, preferably in the pH range 4- 4.5, which is amenable for I. M. or I.V. administration directly without further pH adjustment. Such a sterile composition was found to be stable. The thermal stability data of amorphous composition containing cefepime and L (+) argnine in injection water is shown in Table 1.
Table 1 Thermal stability of amorphous composition containing cefepime and L (+) arginine in injection water.
Amorphous composition of cefepime hydrochloride and L- (+) arginine (gm) was dissolved in injection water and analyzed as per USP method.
Since the aqueous solution of cefepime acid addition salt and arginine has a pH of 4-6, it does not lead to corrosion of the reactor vessel unlike in prior-art methods.
The present invention is described in the following non-limiting examples.
The starting material i. e. composition containing admixture of crystalline cefepime dihydrochloride monohydrate and L (+) arginine available from the market was used. The spray drying was carried out by using Buchi mini spray dryer B-191.
Example 1
To water (250 ml) precooled to 0-50C, cefepime hydrochloride (63 gm) and L- (+) arginine (33 gm) was added and stirred for 10-15 minutes to get clear solution. A solution of L (+) arginine (5 gm) in water (35 ml) was added to obtain pH 4.7 slowly in 10- 15 minutes at 0-50C and stirred for 10-15 minutes. The clear solution was filtered through 0.2 micron membrane filter at 0-50C. Filtrate was subjected for spray drying in the following setting of spray dryer.
Yield of spray-dried composition was 82 gm and HPLC purity was 99.28% (by excluding peak for arginine).
Example 2
Composition containing cefepime dihydrochloride monohydrate and L-arginine (50 gm) was dissolved in demineralized water (50 ml) at 25-300C. The clear solution was filtered through 0.2 micron membrane filter. Filter was washed with water (10 ml). Combined filtrate was subjected for spray drying in the following setting of spray dryer.
Yield of spray-dried composition was 48 gm.
Claims
1. Amorphous composition containing cefepime acid addition salt or solvates thereof and organic or inorganic base obtained by spray drying of their aqueous solution.
2. According to claim 1 wherein, suitable acid addition salts of cefepime which can be used in the composition include H2SO4, di-HNO3, HCI, di-HCI, and SeSqUi-H3PO4 salts and their solvates, most preferably dihydrochloride monohydrate.
3. According to claim 1 wherein, suitable non-toxic organic or inorganic bases which may be used in the composition according to the invention include, for example, sodium citrate, potassium citrate, N-methylglucosamine, N- methylglucamine, L (+) lysine, L (+) arginine tris (hydroxymethyl) aminomethane, NaHCO3, Na2CO3, NaH2PO4, Na2HPO4, Na3PO4, KHCO3, K2CO3, KH2PO4, K2HPO4 and K3PO4, most preferred bases are L (+) lysine and L (+) arginine.
4. A process to obtain amorphous composition containing cefepime acid addition salt or solvates thereof and organic or inorganic base that comprises of, (i) dissolving a composition containing mixture of cefepime acid addition salt and a pharmaceutically acceptable non-toxic organic or inorganic base in water to obtain aqueous solution, (ii) filtration of aqueous solution through 0.2 micron membrane filter and (iii) subjecting the clear aqueous solution to spray drying.
5. A process to obtain amorphous composition containing cefepime acid addition salt or solvates thereof and organic or inorganic base that comprises of,
(i) dissolving a cefepime acid addition salt in water, (ii) dissolving a pharmaceutically acceptable non-toxic organic or inorganic base in water, (iii) addition of solution from operation (v) to solution from operation (iv) at 0-300C, preferably at 0-1O0C to obtain a solution having a pH in the range of 3.0-7.0,
(iv) filtration of aqueous solution through 0.2 micron membrane filter and (v) subjecting the clear aqueous solution to spray drying.
6. A process according to claim 4 and 5 wherein, suitable acid addition salts of cefepime which can be used in the composition according to the invention include H2SO4, di-HNO3, HCI, di-HCI, and sesqui-H3PO4 salts and their solvates, most preferably dihydrochloride monohydrate.
7. A process according to claim 4 and 5 wherein, suitable non-toxic organic or inorganic bases which may be used in the composition according to the invention include, for example, sodium citrate, potassium citrate, N- methylglucosamine, N-methylglucamine, L (+) lysine, L (+) arginine tris(hydroxymethyl) aminomethane, NaHCO3, Na2COa, NaH2PO4,
Na2HPO4, Na3PO4, KHCO3, K2CO3, KH2PO4, K2HPO4 and K3PO4, most preferred bases are L (+) lysine and L (+) arginine.
8. A process according to claim 4 and 5 wherein, aqueous solution has pH in the range of 3.0-7.0, preferably 4.0 to 5.0.
9. A process according to claim 4 and 5 wherein, the molar ratio of cefepime acid addition salt to the pharmaceutically acceptable base in the composition can be in the range of 1:1 to 1 :5, preferably in the range of 1 : 2 to 1:3.
10. A process according to claim 4 and 5 wherein, the solution in water was prepared at 0-300C, preferably at 0-100C, most preferably at 0-50C.
11. A process according to claim 4 and 5 wherein, the pH of the solution was in the range 4-7, preferably 4.0 to 5.0.
12. A process according to claim 5 wherein, addition of solution from operation (v) to solution from operation (iv) was carried out at 0-300C, preferably at 0- 1O0C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN274KO2005 | 2005-04-05 | ||
| IN274/KOL/2005 | 2005-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006106529A1 true WO2006106529A1 (en) | 2006-10-12 |
Family
ID=36809617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2006/000114 WO2006106529A1 (en) | 2005-04-05 | 2006-04-03 | A co-spray dried composition of cefepime with base and process for preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006106529A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011078831A1 (en) * | 2009-12-25 | 2011-06-30 | Mahmut Bilgic | Improved pharmaceutical compositions comprising cefdinir |
| WO2011139249A3 (en) * | 2010-05-04 | 2012-03-01 | Mahmut Bilgic | Pharmaceutical composition comprising cefdinir |
| CN102382125A (en) * | 2011-07-29 | 2012-03-21 | 成都市考恩斯科技有限责任公司 | Cefditoren water-soluble composite, preparation method and corresponding pharmaceutical preparation thereof |
| US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
| CN114042048A (en) * | 2021-10-29 | 2022-02-15 | 海南海灵化学制药有限公司 | Preparation process of cefepime hydrochloride for injection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| EP0695548A1 (en) * | 1994-08-03 | 1996-02-07 | Meiji Seika Kaisha Ltd. | A stably storable and readily water soluble composition of cephalosporin for injections |
| WO2005094800A2 (en) * | 2004-03-31 | 2005-10-13 | Lupin Ltd. | A co-precipitated cefepime composition and process for preparation thereof |
-
2006
- 2006-04-03 WO PCT/IN2006/000114 patent/WO2006106529A1/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| EP0695548A1 (en) * | 1994-08-03 | 1996-02-07 | Meiji Seika Kaisha Ltd. | A stably storable and readily water soluble composition of cephalosporin for injections |
| WO2005094800A2 (en) * | 2004-03-31 | 2005-10-13 | Lupin Ltd. | A co-precipitated cefepime composition and process for preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| HANCOCK B C ET AL: "CHARACTERISTICS AND SIGNIFICANCE OF THE AMORPHOUS STATE IN PHARMACEUTICAL SYSTEMS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 86, no. 1, January 1997 (1997-01-01), pages 1 - 12, XP000929450, ISSN: 0022-3549 * |
| HILDEN L R ET AL: "Physics of amorphous solids", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 93, no. 1, January 2004 (2004-01-01), pages 3 - 12, XP002368266, ISSN: 0022-3549 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011078831A1 (en) * | 2009-12-25 | 2011-06-30 | Mahmut Bilgic | Improved pharmaceutical compositions comprising cefdinir |
| US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
| WO2011139249A3 (en) * | 2010-05-04 | 2012-03-01 | Mahmut Bilgic | Pharmaceutical composition comprising cefdinir |
| CN102382125A (en) * | 2011-07-29 | 2012-03-21 | 成都市考恩斯科技有限责任公司 | Cefditoren water-soluble composite, preparation method and corresponding pharmaceutical preparation thereof |
| CN114042048A (en) * | 2021-10-29 | 2022-02-15 | 海南海灵化学制药有限公司 | Preparation process of cefepime hydrochloride for injection |
| CN114042048B (en) * | 2021-10-29 | 2023-02-28 | 海南海灵化学制药有限公司 | Preparation process of cefepime hydrochloride for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3852946B2 (en) | Crystalline ceftiofur free acid | |
| KR840001776B1 (en) | Process for preparing seftazidime pentahydrate | |
| CA1298288C (en) | Cephalosporin salts and injectable compositions | |
| PL172835B1 (en) | 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae | |
| WO2006106529A1 (en) | A co-spray dried composition of cefepime with base and process for preparation thereof | |
| KR101577488B1 (en) | Cefdinir acid double salt and its preparation | |
| US5595986A (en) | Stably storable and readily water soluble composition of cephalosporin for injections | |
| AU597262B2 (en) | Cephalosporin salts and injectable compositions | |
| WO2005094800A2 (en) | A co-precipitated cefepime composition and process for preparation thereof | |
| FI65069C (en) | FORM OF THE CRYSTALS OF THE CRYSTALS OF THE CRYSTALS IN FORM AV SODIUM-7- (D-ALPHA-FORMYLOXY-ALPHA-PHENYLACETAMIDO) -3- (1-METHYL-1H-TETRAZOLE-5-YLTHOMETHYL) -3-CARFEM | |
| WO2006109324A2 (en) | Processes for preparation of amorphous cefepime acid addition salts | |
| JPH01110690A (en) | Water-soluble antibiotic composition and water-soluble salts of novel cephem compound | |
| JP2958567B2 (en) | Freeze-dried BMY-28142 dihydrochloride for parenteral use | |
| EP0443471B1 (en) | 2'-Deoxy-2'-methylidenecytidine dihydrate, methods for its production and compositions | |
| JPH0613525B2 (en) | New crystalline ceftazidine, its production method and pharmaceutical preparation | |
| US5244891A (en) | Injectable compositions of cefepime dihydrochloride hydrate | |
| US4994451A (en) | Cephalosporin salts and injectable compositions | |
| JP2572563B2 (en) | A new stable crystalline form of the cephalosporin intermediate. | |
| JPH06247974A (en) | Cephalosporin salt and its preparation | |
| WO2008056221A2 (en) | Crystalline sulfate salt of cephalosporin antibiotic | |
| HUT72494A (en) | Stable and readily water soluble composition for injection containing cephalosporin | |
| JPS60228487A (en) | 7-(alpha(2-amino-4-thiazolyl)-alpha-(lower alkoxyimino)acetamide)-3-substituted pyridiniomethyl-delta3-cephem-4-carboxylate and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06728419 Country of ref document: EP Kind code of ref document: A1 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 6728419 Country of ref document: EP |